Express Mail Label No.: EV199928096US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

First Named Inventor: Bernhard KEPPLER

§ §

Conf. No.: Not Yet Assigned Group Art Unit: Not Yet Assigned

Appln. No.: Not Yet Assigned

Examiner: Not Yet Assigned

Filing Date: Herewith Attorney Docket No.: 8182-25US

(PA32424US)

Title: COMPOSITIONS CONTAINING A RUTHENIUM(III) COMPLEX AND A

HETEROCYCLE

INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. §1.97(b)

Enclosed are copies of each of the documents listed on the attached Information Disclosure Citation Form(s) PTO/SB/08A and/or B, which may be material to the patentability of this application and/or for which there may be a duty to disclose in accordance with 37 C.F.R. §1.56.

Some of the enclosed references were cited in either an International Search Report (copy enclosed) dated June 28, 2002 from the European Patent Office concerning counterpart International Application No. PCT/EP02/00863 or at pages 1 and 2 of the specification. Additional references are also enclosed.

The filing of this Information Disclosure Statement shall not be construed as an admission that any of the listed documents constitutes prior art, nor as an admission against interest in any manner.

No fee is believed to be due in connection with the filing of this Information Disclosure Statement since it is being filed within three months of the filing date of the above-identified application. However, the Commissioner is hereby authorized to charge any deficiencies or credit any overpayments to Deposit Account No. 50-1017.

It is respectfully requested that this Information Disclosure Statement and the documents listed on the attached Form PTO/SB/08A and/or B be considered and acknowledged by the Examiner in connection with the above-identified patent application, be made of record therein, and that the listed document(s) be cited in the issued patent.

Respectfully submitted,

Bernhard KEPPLER

Instyre p. bullal (Reg. No. 42371) for William W. Schwarze

Attorney/Agent for Applicant(s)

Registration No. 25,918 Direct Dial: 215-965-1270

E-Mail: wschwarze@akingump.com

Akin Gump Strauss Hauer & Feld LLP

One Commerce Square 2005 Market Street, Suite 2200

Philadelphia, PA 19103 Telephone No.: 215-965-1200

Fax No.: 215-965-1210

WWS:srn
Enclosures

Form PTO/SB/08A				Complete if Known		
			001107	Application Number	Not Yet Assigned	
			OSURE	Filing Dat	Herewith	
SIAIE	WENTE	BY APPL	LICANI	First Named Invent r	Bernhard KEPPLER	
/usa s	e many el	heets as n	ococcan/)	Gr up Art Unit	Not Yet Assigned	
	as many si	116612 02 11	ecessary)	Examin r Name	Not Yet Assigned	
Sheet	1	of	1	Attorney Docket Number	8182-25US (PA32424US)	

Exr Initials	U.S. Patent Docume	ent	Name of First Inventor of Cited Document	Date of Publication of Cited Document MM-YYYY	
	Number	Kind Code (if known)			
	4,843,069		KELLER et al.	06-1989	

			FOREIGN PATE	NT DOCUMENTS		
		Foreign Patent Docum	ent	Name of Applicant of Cited Document	Date of Publication of Cited Document MM-YYYY	T ₁
Exr Initials	Country Code	Number	Kind Code (if known)			
	wo	97/36595	A2	Richard-Wagner-Strasse	10-1997	*X
		***************************************			*****	
				*Abstract Only	- 100 m	-

	OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS	
Exr Initials	Include Name of first Author (in CAPITAL LETTERS), title of the article (where appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), volume-issue number(s), page(s), date (in parentheses). If a book, also include publisher and city and/or county where published.	T.
1	F.T. GARZON et al., "Comparative antitumor activity of ruthenium derivatives with 5'-deoxy-5-fluorouridine in chemically induced colorectal tumors in SD rats", Cancer Chemother Pharmacol, pp. 347-349, (1987)	
<u> </u>	B.K. Keppler et al., "New Ruthenium Complexes for the Treatment of Cancer", <i>Progress in Clinical Biochemistry and Medicine</i> , Vol. 10, pp. 41-69, (1989)	
/	H. DEPENBROCK et al., "Preclinical Activity of Trans-indazolium [Tetrachlorobisindazoleruthenate (III)] (NSC 666158; IndCR; KP 1019) Against Tumour Colonyforming Units and Haematopoietic Progenitor Cells", <i>European Journal of Cancer</i> , Vol. 33, No. 14, pp. 2404-2410, (1997)	
	A.GALEANO et al., "Antitumor Activity of Some Ruthenium Derivatives in Human Colon Cancer Cell Lines in vitro", <i>ArzneimForsch./Drug Res.</i> , 42, Vol. 1, No. 6, pp. 821-824, (1992)	
_	F. KRATZ et al., "Protein-Binding Properties Of Two Antitumour Ru(III) Complexes To Human Apotransferrin And Apolactoferrin", <i>Metal-Based Drugs</i> , Vol. 1, Nos. 2-3, pp. 169-173 (1994)	
	F. KRATZ et al., "Comparison Of The Antiproliferative Activity Of Two Antitumour Ruthenium(III) Complexes With Their Apotransferrin And Transferrin-Bound Forms In A Human Colon Cancer Cell Line", <i>Metal-Based Drugs</i> , Vol. 3, No. 1, pp. 15-23, (1996)	
/	Y.N. VASHISHT GOPAL et al., "Topoisomerase II poisoning by indazole and imidazole complexes of ruthenium", <i>J. Biosci</i> , Vol. 26, No. 2, pp. 271-276, (2001)	
/	ERNST D. KREUSER et al., "Synergistic Antitumor Interactions Between Newly Synthesized Ruthenium Complexes and Cytokines in Human Colon Carcinoma Cell Lines", <i>Seminars in Oncology</i> , Vol. 19, No. 2 Suppl 3, pp. 73-81, (1992)	
1	S. PACOR et al., "Antitumor action of mer-trichlorobis (dimethylsulphoxide) aminoruthenium (III) (BBR2382) in mice bearing lewis lung carcinoma", <i>Metal Ions in Biology and Medicine</i> , pp. 482-484, (1990)	

Examiner	Date
	1 24.0
Signature	Considered
Olgitation	Considered